/
DBVT
$14.03-$0.11 (-0.78%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$888.6M
63M shares
52-week range
$8.70 – $26.19
30% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-34.77
DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
www.dbv-technologies.com- Employees
- 170
- IPO / List date
- Oct 22, 2014
- HQ
- CHATILLON, I0
Held by traders on TradeandTell
No one on the platform currently holds DBVT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in DBVT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-11-29 | 1-for-5reverse |
| 2024-06-07 | 1-for-2reverse |
Recent trades on TradeandTell
No one on the platform has traded DBVT yet.
